FDA Fast Track Designation for LOAd703 for the treatment of Pancreatic Cancer
This is an important milestone for Lokon Pharma, said Dr. Angelica Loskog (CEO/CSO). She continues, “Pancreatic cancer is a remaining challenge within immune oncology. Lokon’s LOAd703 gene engineers the TME to express strong immune activators and thereby induces an inflammation that can sensitize these patients to traditional immunotherapy with checkpoint blockade antibodies. LOAd703 is currently evaluated in combination with gemcitabine and nab-paclitaxel plus an anti-PD-L1 antibody in pancreatic cancer and a randomized phase II study is on the way.”
Share:
More News
PharmaMar has submitted a Marketing Authorization Application to the European Medicines Agency for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer, whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. The MAA submission
“At SR One, our mission is to invest in companies that we believe have the ability to innovate and advance transformational new therapies in areas of high unmet medical need,” said Simeon George, M.D., Chief Executive Officer and Managing Partner at SR One. “Fore Bio is focused on resetting the
The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of TACE-progression-free survival (TACE PFS*), and the other primary endpoint of overall survival (OS) is immature at the prespecified first interim analysis. Meanwhile, a clinically meaningful PFS by RECIST v1.1** was also observed. Detailed findings from
“The positive CHMP recommendation for the Itovebi-based regimen represents a significant step towards providing people in the EU with PIK3CA-mutated, ER-positive advanced breast cancer with a targeted therapy in the first-line setting,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This recommendation is
